Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 28, 2014Cancer DiscoveryOpen Access

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

LFLuc FribouletInsermNLNanxin LiSichuan Agricultural UniversityRKRyohei KatayamaJapanese Foundation For Cancer Research

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Friboulet et al. (2014) studied this question.

synapsesocial.com/papers/69dc3a568df84278519f5342https://doi.org/10.1158/2159-8290.cd-13-0846
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cell culture and<i>Drosophila</i>model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma2012 · 60 citations
  2. 2EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors2010 · 1,192 citations
  3. 3Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer2014 · 1,477 citations
  4. 4<i>ALK</i> Rearrangements Are Mutually Exclusive with Mutations in <i>EGFR</i> or <i>KRAS</i>: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer2013 · 615 citations
  5. 5Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance2012 · 98 citations